Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
New Strategies for Individualizing Treatment in DME
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
Time Is Bone: Making the Case for Early Anabolic Treatment in Osteoporosis
Kendall Moseley, MD
Kenneth G. Saag, MD
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Marilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Vera Bril, MD
Nicholas J. Silvestri, MD
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Hans Katzberg, MD
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Ocular to Generalized MG: How and Why the Disease Evolves
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
Diagnostic Advances in gMG: Effective Tools and Techniques
What’s New in Suprachoroidal MIGS?
Effective MIGS for Optimal IOP Control: A Case-Based Approach
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.